{"id":"NCT01124643","sponsor":"Shire","briefTitle":"Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease","officialTitle":"An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal® Enzyme Replacement Therapy Administered to Adult Patients With Fabry Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04-13","primaryCompletion":"2013-07-08","completion":"2013-07-08","firstPosted":"2010-05-17","resultsPosted":"2014-08-22","lastUpdate":"2021-06-08"},"enrollment":35,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fabry Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Replagal","otherNames":["algalsidase alfa","alpha-Galactosidase","DRX005B"]}],"arms":[{"label":"Replagal 0.2 mg/kg EOW","type":"EXPERIMENTAL"}],"summary":"This study will evaluate safety and clinical outcomes of treatment with Replagal in adult participants with Fabry disease who have completed Study TKT028 (NCT00864851).","primaryOutcome":{"measure":"Change From Baseline in Left Ventricular Mass Indexed to Height (LVMI)","timeFrame":"Baseline to 12 months","effectByArm":[{"arm":"Replagal® (0.2 mg/kg)","deltaMin":-0.75,"sd":13.46}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":9,"countries":["United States","Australia","Czechia","Finland","Poland","Slovenia","United Kingdom"]},"refs":{"pmids":["26185417"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":35},"commonTop":["Nasopharyngitis","Diarrhoea","Headache","Bronchitis","Pain in extremity"]}}